COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- China's urban unemployment rate falls to 5.1% in May
- Mainland slams DPP's intel platform, vows countermeasures
- Wuhan's robot trainers speak of small roles in big task
- DPP seeks 'illusory' separatist status quo: mainland spokesman
- China to host inaugural Xiong'an Global Governance Forum
- Eastern corridor of China-Europe freight train network witnesses over 40,000 trips
